Genexine, Inc.
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1999-06-08
- Employees
- 101
- Market Cap
- -
- Website
- http://www.genexine.com
Clinical Trial of Efepoetin Alfa in Healthy Subjects
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06490939
- Locations
- 🇰🇷
Hanyang University Medical Center, Seoul, Korea, Republic of
A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis
- Conditions
- Anemia of Chronic Kidney Disease
- Interventions
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 429
- Registration Number
- NCT06466785
- Locations
- 🇬🇪
Batumi Dialysis and Nephrology Center, Batumi, Georgia
🇬🇪Clinical Center for Nephrology Development, Tbilisi, Georgia
🇬🇪L.Managadze National Center of Urology, Tbilisi, Georgia
GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients
- Conditions
- Recurrent Glioblastoma
- Interventions
- First Posted Date
- 2022-01-13
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05191784
- Locations
- 🇰🇷
Seoul St.Mary's Hospital of the Catholic University of Korea, Seoul, Korea, Republic of
Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 Vaccines
- Conditions
- SARS-CoV2 Infection
- Interventions
- Biological: GX-19NOther: Placebo
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Genexine, Inc.
- Registration Number
- NCT05067946
Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04915989
- Locations
- 🇰🇷
Severance hospital, Seoul, Korea, Republic of
🇰🇷Gangnam Severance hospital, Seoul, Korea, Republic of
Safety and Preliminary Efficacy Study of GX-I7 in Patients With COVID-19
- First Posted Date
- 2021-01-29
- Last Posted Date
- 2022-11-30
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04730427
- Locations
- 🇰🇷
Borame Medical Center, Seoul, Korea, Republic of
Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults
- First Posted Date
- 2021-01-20
- Last Posted Date
- 2021-12-09
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 170
- Registration Number
- NCT04715997
- Locations
- 🇰🇷
KyungHee University Medical Center, Seoul, Korea, Republic of
🇰🇷Severance Hospital, Seoul, Korea, Republic of
🇰🇷Hanyang University Hospital, Seoul, Korea, Republic of
Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2021-12-09
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT04445389
- Locations
- 🇰🇷
Severance hospital, Seoul, Korea, Republic of
Safety and Tolerability of GX-P1 in Healthy Male Volunteers
- Conditions
- Autoimmune Diseases
- Interventions
- Drug: GX-P1 or Placebo (dose level 2)Drug: GX-P1 or Placebo (dose level 3)Drug: GX-P1 or Placebo (dose level 1)
- First Posted Date
- 2020-03-06
- Last Posted Date
- 2021-07-27
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04298749
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Individual Patient Compassionate Use of GX-I7
- Conditions
- GlioblastomaHigh Grade GliomaRecurrent GlioblastomaMelanomaAdvanced Cancer
- First Posted Date
- 2020-02-28
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- Genexine, Inc.
- Registration Number
- NCT04289155
- Locations
- 🇰🇷
Kangnam St. Mary's Hospital, Seoul, Korea, Republic of